[go: up one dir, main page]

JO3261B1 - مشتق بيريدين أحادي الحلقة - Google Patents

مشتق بيريدين أحادي الحلقة

Info

Publication number
JO3261B1
JO3261B1 JOP/2014/0039A JOP20140039A JO3261B1 JO 3261 B1 JO3261 B1 JO 3261B1 JO P20140039 A JOP20140039 A JO P20140039A JO 3261 B1 JO3261 B1 JO 3261B1
Authority
JO
Jordan
Prior art keywords
group
hydrogen atom
present
alkoxy
pharmaceutically acceptable
Prior art date
Application number
JOP/2014/0039A
Other languages
English (en)
Inventor
Ohashi Isao
Okada Toshimi
Nagao Satoshi
Funasaka Setsuo
Tanaka Keigo
Nakatani Yusuke
Yamane Yoshinobu
Karoji Yuki
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of JO3261B1 publication Critical patent/JO3261B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتقديم مركب جديد له نشاط مثبط لـ FGFR أو ملح مقبول صيدلانيا منه، وتركيبة صيدلانية تتضمنه. بصفة خاصة، يقدم الاختراع الحالي مركب ممثل بالصيغة التالية (I) أو ملح مقبول صيدلانيا منه: حيث n تمثل 0 الى 2؛ A تمثل مجموعة أريلين أو مجموعة أريلين غير متجانسة؛ G تمثل رابطة فردية، ذرة أكسجين أو -CH 2 - ؛ E تمثل سيكل غير متجانسة غير عطرية تتضمن نيتروجين؛ R1 تمثل مجموعة ألكوكسي، مجموعة ألكوكسي ألكوكسي أو ما شابه ذلك؛ R2 تمثل ذرة هيدروجين، ذرة هالوجين، مجموعة هيدروكسيل، مجموعة ألكيل، مجموعة هيدروكسي ألكيل، مجموعة سيكليك غير متجانسة غير عطرية تتضمن نيتروجين أو ما شابه ذلك؛ و R3 تمثل ذرة هيدروجين، مجموعة ألكيل، مجموعة ألكوكسي أو ما شابه ذلك، بشرط أنه عندما تكون E تمثل حلقة أزيتيدين و R2 أو تكون R3 موجودة على ذرة نيتروجين على حلقة الأزيتيدين، R2 أو R3 لا تمثل ذرة هيدروجين.
JOP/2014/0039A 2013-02-20 2014-02-18 مشتق بيريدين أحادي الحلقة JO3261B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361766922P 2013-02-20 2013-02-20

Publications (1)

Publication Number Publication Date
JO3261B1 true JO3261B1 (ar) 2018-09-16

Family

ID=51351646

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0039A JO3261B1 (ar) 2013-02-20 2014-02-18 مشتق بيريدين أحادي الحلقة

Country Status (35)

Country Link
US (1) US8933099B2 (ar)
EP (1) EP2960238B1 (ar)
JP (2) JP5600229B1 (ar)
KR (1) KR102050128B1 (ar)
CN (1) CN105073730B (ar)
AR (1) AR094812A1 (ar)
AU (1) AU2014219811B2 (ar)
BR (1) BR112015019790B1 (ar)
CA (1) CA2901585C (ar)
CL (1) CL2015002311A1 (ar)
CY (1) CY1119220T1 (ar)
DK (1) DK2960238T3 (ar)
ES (1) ES2628495T3 (ar)
HR (1) HRP20170873T1 (ar)
HU (1) HUE032931T2 (ar)
IL (1) IL240623B (ar)
JO (1) JO3261B1 (ar)
LT (1) LT2960238T (ar)
ME (1) ME02755B (ar)
MX (1) MX361870B (ar)
MY (1) MY178760A (ar)
NZ (1) NZ711101A (ar)
PE (1) PE20151509A1 (ar)
PH (1) PH12015501813A1 (ar)
PL (1) PL2960238T3 (ar)
PT (1) PT2960238T (ar)
RS (1) RS56064B1 (ar)
RU (1) RU2645352C2 (ar)
SG (1) SG11201506488WA (ar)
SI (1) SI2960238T1 (ar)
SM (1) SMT201700288T1 (ar)
TW (4) TWI672139B (ar)
UA (1) UA116794C2 (ar)
WO (1) WO2014129477A1 (ar)
ZA (1) ZA201505941B (ar)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016027781A1 (ja) * 2014-08-18 2016-02-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 単環ピリジン誘導体の塩およびその結晶
RU2712222C2 (ru) * 2015-03-25 2020-01-27 Нэшнл Кэнсер Сентер Терапевтическое средство против рака желчных протоков
AU2016374441B2 (en) * 2015-12-17 2021-10-21 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
SG11202001481PA (en) * 2017-10-12 2020-03-30 Eisai R&D Man Co Ltd Pharmaceutical composition comprising fgfr selective tyrosine kinase inhibitor
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4122465A4 (en) 2020-04-17 2024-03-20 Eisai R&D Management Co., Ltd. THERAPEUTIC AGENT AGAINST BREAST CANCER
CA3185174A1 (en) * 2020-07-31 2022-02-03 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
CN116390757A (zh) 2020-10-28 2023-07-04 卫材R&D管理有限公司 用于治疗肿瘤的药物组合物
US20240294496A1 (en) * 2021-08-31 2024-09-05 Eisai R&D Management Co., Ltd. Production method for synthetic intermediate of monocyclic pyridine derivative
CN117715902A (zh) 2021-08-31 2024-03-15 卫材R&D管理有限公司 单环吡啶衍生物的制造方法
US20250171415A1 (en) * 2022-03-18 2025-05-29 Shanghai Runshi Medical Technology Co., Ltd. Salt of substituted amino six-membered nitric heterocyclic compound, crystal form thereof, method for preparing same, and use thereof
CN120021412A (zh) * 2023-09-18 2025-05-20 上海润石医药科技有限公司 包含杂芳基氧基萘类化合物的药物组合物及其制备方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
WO2002081420A1 (en) 2001-04-03 2002-10-17 Eisai Co., Ltd. Cyclooctanone derivative and cyclodecanone derivative, and use thereof
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CN100339376C (zh) 2002-08-30 2007-09-26 卫材R&D管理有限公司 含氮芳环衍生物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
MXPA05010765A (es) 2003-04-10 2005-12-12 Hoffmann La Roche Compuestos pirimido.
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
AU2006249847B2 (en) * 2005-05-23 2012-12-20 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
MEP3808A (xx) 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1891955A1 (en) 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
EP2158471A1 (en) 2007-06-25 2010-03-03 Qinetiq Limited Heater suitable for use in a preconcentrator device
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
WO2009076660A2 (en) * 2007-12-13 2009-06-18 Tyratech, Inc. Organic absorbent material and uses thereof
CL2008003675A1 (es) * 2007-12-13 2009-03-20 Wyeth Corp Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide.
ES2554513T3 (es) 2008-05-23 2015-12-21 Novartis Ag Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2009153592A1 (en) 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
WO2010078427A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
CN102325755B (zh) 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
WO2010078430A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
US9002427B2 (en) 2009-03-30 2015-04-07 Lifewave Biomedical, Inc. Apparatus and method for continuous noninvasive measurement of respiratory function and events
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
AR084370A1 (es) 2009-08-07 2013-05-15 Chugai Pharmaceutical Co Ltd Derivados de aminopirazol
KR20120101367A (ko) 2009-10-30 2012-09-13 노파르티스 아게 3-（2,6-디클로로-3,5-디메톡시-페닐）-1-｛6-［4-（4-에틸-피페라진-1-일）-페닐아미노］-피리미딘-4-일｝-1-메틸-우레아의 ｎ-옥시드
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
AU2013210403B2 (en) 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
AU2013227139B2 (en) 2012-02-28 2017-02-16 Astellas Pharma Inc. Nitrogen-containing aromatic heterocyclic compound
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
CN104540809B (zh) 2012-07-11 2018-12-11 蓝印药品公司 成纤维细胞生长因子受体的抑制剂
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
ES2643571T3 (es) 2012-09-27 2017-11-23 Chugai Seiyaku Kabushiki Kaisha Gen de fusión FGFR3 y fármaco que se dirige al mismo
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑

Also Published As

Publication number Publication date
WO2014129477A1 (ja) 2014-08-28
EP2960238A4 (en) 2016-08-17
LT2960238T (lt) 2017-07-10
NZ711101A (en) 2018-08-31
TW201900169A (zh) 2019-01-01
ES2628495T3 (es) 2017-08-03
SMT201700288T1 (it) 2017-07-18
HK1215949A1 (en) 2016-09-30
CL2015002311A1 (es) 2016-02-05
CN105073730A (zh) 2015-11-18
AU2014219811B2 (en) 2017-09-28
RU2645352C2 (ru) 2018-02-21
ZA201505941B (en) 2016-07-27
HRP20170873T1 (hr) 2017-09-08
BR112015019790A2 (pt) 2017-07-18
US8933099B2 (en) 2015-01-13
AU2014219811A1 (en) 2015-09-03
PE20151509A1 (es) 2015-10-18
AR094812A1 (es) 2015-08-26
TWI672139B (zh) 2019-09-21
MY178760A (en) 2020-10-20
TWI641602B (zh) 2018-11-21
IL240623A0 (en) 2015-10-29
PL2960238T3 (pl) 2017-09-29
TW201900168A (zh) 2019-01-01
JP2014237707A (ja) 2014-12-18
EP2960238A1 (en) 2015-12-30
BR112015019790B1 (pt) 2020-12-01
PH12015501813A1 (en) 2015-12-07
TWI672140B (zh) 2019-09-21
US20140235614A1 (en) 2014-08-21
KR102050128B1 (ko) 2019-11-28
JP5600229B1 (ja) 2014-10-01
IL240623B (en) 2019-03-31
UA116794C2 (uk) 2018-05-10
RU2015134558A (ru) 2017-03-24
TWI672296B (zh) 2019-09-21
TW201902889A (zh) 2019-01-16
PT2960238T (pt) 2017-06-05
TW201439085A (zh) 2014-10-16
CY1119220T1 (el) 2018-02-14
CA2901585C (en) 2019-09-24
RS56064B1 (sr) 2017-10-31
HUE032931T2 (en) 2017-11-28
CN105073730B (zh) 2017-10-13
MX361870B (es) 2018-12-18
MX2015010698A (es) 2016-04-11
DK2960238T3 (en) 2017-06-26
CA2901585A1 (en) 2014-08-28
KR20150118151A (ko) 2015-10-21
SG11201506488WA (en) 2015-09-29
SI2960238T1 (sl) 2017-07-31
EP2960238B1 (en) 2017-04-05
ME02755B (me) 2018-01-20
JPWO2014129477A1 (ja) 2017-02-02

Similar Documents

Publication Publication Date Title
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
UA118259C2 (uk) Гетероциклічні аміди як інгібітори кінази
MX2017010735A (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EA201690127A1 (ru) Состав на основе ингибиторов syk
NZ710052A (en) Novel pyrazol derivatives
MX2017005158A (es) Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk).
IN2014DN07283A (ar)
PH12018501181A1 (en) Phenyl derivatives as cannabinoid receptor 2 agonists
MX368178B (es) Compuestos de ácido dimetilbenzoico.
MX2015017156A (es) Inhibidores de bace.
PH12020500292A1 (en) Pyridine compound substituted with azole
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
PH12018502012B1 (en) Griseofulvin compound
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
PH12016500152A1 (en) Novel triazine derivative
MD20150103A2 (ro) Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
MX2015007309A (es) Derivado de hidantoina.
PH12016501645A1 (en) Aminopyrazolone derivative
MX345264B (es) Derivado de azol.